Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

Completed · Phase 3

Conditions studied: Hyperlipidemia and Mixed Dyslipidemia

In brief

This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.

Key facts

Study ID
NCT01854918
Run by
Amgen
People needed
3681
Starts
2013-04-23
Expected to finish
2018-05-31
Last updated by the study team
2019-06-11

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.